Report Summary 1. Report Industry Investment Rating No information provided in the document. 2. Core Viewpoints - The company is the first in China to successfully put into production a TBS production device. TBS has excellent performance and a wide range of downstream applications, with good market prospects under the trend of industrial upgrading and import substitution [24][37]. - The company attaches great importance to the strategic value and development potential of cutting - edge technology fields such as synthetic biology. The Taizhou project (Phase I) is an extension of the company's product matrix and technology accumulation, aiming to enrich product categories [25][30][32]. - The company's R & D adopts a model of internal R & D combined with university cooperation. The existing R & D team is mainly composed of senior technical backbones with over 10 years of industry experience, which is in line with the current R & D needs of the company [27][28]. - The company's products are mainly high - molecular new material special monomers and special additives, which have the characteristics of small dosage, great effect, and high added value in the downstream high - molecular new material industry system [38]. 3. Summary According to the Directory 3.1 Research Basic Situation - The research object is Changqing Technology. The reception time was on September 26, 2025. The listed company's reception personnel included the chairman and general manager, the director and board secretary, the financial controller, and the independent director [17]. 3.2 Detailed Research Institutions - The research institutions mainly include investors and others [20]. 3.3 Research Institution Proportion No information provided in the document. 3.4 Main Content Information - **Product Application and Market**: TBS has been sent for sampling and sales in multiple industries and is expected to be applied in more industries. The company's products can be used in multiple fields of the big - health industry, such as high - end medical consumables, biomedicine, and food packaging [24][26]. - **Project Planning**: The Taizhou project (Phase I) is an extension of the company's product matrix and technology accumulation. The second - and third - phase plans will be scientifically demonstrated and decided based on the operation results of the first - phase project, market trends, and R & D progress [25][30][35]. - **New Product Promotion and Production Capacity**: Some new products of the company's fund - raising projects have been sent to customers for sampling or obtained orders, and the production capacity and benefits are gradually being released. The seventh - phase project is in the trial - production stage [27][31][41]. - **R & D and Technology**: The company's R & D adopts a combination of internal R & D and university cooperation. The company's unique technology path is difficult to be imitated by competitors, and the company attaches great importance to technology confidentiality [27][28][34]. - **Market and Sales**: The company's products are sold overseas, with an export proportion of about 35% during the reporting period, mainly to Europe, Japan, South Korea, Southeast Asia and other countries or regions [24][33][37]. - **Production Capacity and Performance**: The company's production capacity is in a stable and rising trend. The production capacity of the fund - raising project is gradually climbing. Regarding the third - quarter performance, please refer to the company's subsequent regular reports [41].